Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This clinical study is designed to evaluate the safety and immune modulatory effects of oral
administration of the study drug anti-CD3 monoclonal antibody (MAb) to subjects with the
metabolic syndrome.